Lung cancer remains the leading cause of cancer-related deaths despite recent
breakthroughs in immunotherapy. The widely embraced cancer stem cell (CSC) theory has …

Histone deacetylases (HDACs) are clinically validated epigenetic drug targets for cancer
treatment. HDACs inhibitors (HDACis) have been successfully applied against a series of …

Drug resistance mediated by clonal evolution is arguably the biggest problem in cancer
therapy today. However, evolving resistance to one drug may come at a cost of decreased …

Non-small cell lung cancer (NSCLC) is known to have poor patient outcomes due to
development of resistance to chemotherapy agents and the EGFR inhibitors, which results in …

Simple Summary Although rare, uveal melanoma (UM) is the most common cancer that
develops inside adult eyes. The prognosis is poor, since 50% of patients will develop lethal …

Lung cancer is indeed a major cause of cancer‐related deaths worldwide. The development
of tumors involves a complex interplay of genetic, epigenetic, and environmental factors …

Epigenetic modulation, including acetylation, methylation, phosphorylation, and
ubiquitination, plays a pivotal role in regulation of gene expression. Histone acetylation—a …

Histone deacetylases (HDACs) are key epigenetic regulators and classified into four
subtypes. Despite the various roles of each HDAC isoform, the lack of selective HDAC …

Simple Summary Histone deacetylase inhibitors (HDACIs) are a relatively new drug class
with important effects on the epigenetic regulation in cancer, inducing cancer cell death …

Lung cancer is one of the most common malignancies. In spite of the progress made in past
decades, further studies to improve current therapy for lung cancer are required …